Physician profile
Sankar Narayan Niranjan
NPI 1497752802
$3,188.50
in general payments reported to CMS, 2019-2025
24 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,682 · 2020: $106 · 2022: $337 · 2023: $497 · 2024: $444 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,063.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Uk Limited | $1,335.76 | 2019 | |
| Baxter Healthcare | $425.65 | 2019-2024 | Renal - Chronic |
| Amgen INC. | $373.94 | 2019-2024 | Aranesp, Tavneos, Parsabiv |
| Idorsia Pharmaceuticals US INC | $122.00 | 2025 | Tryvio |
| Travere Therapeutics, INC. | $102.73 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $99.26 | 2020-2023 | |
| Aurinia Pharma U.S., INC. | $75.39 | 2022 | |
| Bard Peripheral Vascular, INC. | $72.55 | 2020 | |
| Alexion Pharmaceuticals, INC. | $72.13 | 2019 | |
| Akebia Therapeutics INC | $65.14 | 2022-2024 | Vafseo, Auryxia |
| Otsuka America Pharmaceutical, INC. | $57.69 | 2019-2023 | Jynarque |
| Glaxosmithkline, LLC. | $57.16 | 2022-2023 | Benlysta |
| Shire North American Group INC | $46.54 | 2019 | |
| Fresenius USA Marketing, INC. | $38.57 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.44 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $29.62 | 2022 | |
| Vifor Pharma, INC. | $29.29 | 2022-2023 | Veltassa |
| Novartis Pharmaceuticals Corporation | $27.53 | 2024 | |
| Horizon Therapeutics Plc | $26.23 | 2023 | Krystexxa |
| Lilly USA, LLC | $22.18 | 2024 | Jardiance |
| Novo Nordisk INC | $20.17 | 2024 | Ozempic |
| Ardelyx, INC. | $19.57 | 2023 | Ibsrela |
| Calliditas Therapeutics US INC. | $17.74 | 2023 | Tarpeyo |
| Mallinckrodt Enterprises LLC | $16.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sankar Niranjan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.